“Screening for prostate cancer has been a public health disaster,” announced Andrew J. Vickers, PhD, Attending Research Methodologist, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York City. At the center of the debate is the question of whether the benefits of prostate-specific antigen (PSA) screening (namely the reduction in mortality) outweigh the harms (overdiagnosis and overtreatment). According to Dr. Vickers and his colleague Peter R. Carroll, MD, MPH, Professor and Chair, Department of Urology, University of California, San Francisco, the answer depends on screening younger men than in the past, adherence to strict criteria for biopsy, aggressive treatment of men with high-risk disease, and active surveillance for men with low-risk disease. Both Drs. Carroll and Vickers are members of the NCCN Guidelines Panel for Prostate Cancer Early Detection.
Dr. Carroll has disclosed that he has received grants or research support from Genomic Health, Inc., and consulting fees or honoraria from Intuitive Surgical, Inc., Jannsen Pharmaceutica Products, LP, Takeda Pharmaceuticals North America, Inc., and TEVA. Dr. Vickers has disclosed that he has received grants or research support from GlaxoSmithKline, royalty income from Arctic Partners, and has served as scientific advisor for Genomic Health, Inc., Genome DX, Ringful Health.
Andriole GL, Crawford ED, Grubb RL 3rd. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–1319.
Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120–134.
Bill-Axelson A, Holmberg L, Garmo H. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–942.
Hugosson J, Carlsson S, Aus G. Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725–732.
Carroll PR, Whitson JM, Cooperberg MR. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol 2011;29:345–347.
Vickers AJ, Sjoberg DD, Ulmert D. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med 2014;12:26.
Savage CJ, Vickers AJ. Low annual caseloads of United States surgeons conducting radical prostatectomy. J Urol 2009;182:2677–2679.
Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29:3669–3676.